- Home
- Browse
- National Institutes of Health
- RFA-MH-27-135
Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
- Deadline
- 2026-10-10
- 37 days left
- Award ceiling
- —
- Awards
- 5
- Posted
- 2026-04-29
Summary
Background Rapid-acting psychotropic interventional drugs (RAPIDs) are a class of psychoactive drugs that produce intense subjective effects and include 5-HT2A agonists such as psilocybin and lysergic acid diethylamide (LSD), dissociative anesthetics such as ketamine, and entactogens such as 3,4-methylenedioxymethamphetamine (MDMA). […]
The rest of this announcement — free with an account
- →The full announcement text, not the first two sentences
- →All 3 review criteria reviewers score this against, extracted from this announcement
- →Whether you are eligible — career stage, institution type, and the windows that close before the deadline does
- →What similar funded projects received, from 219,000 past awards
No card required. Browsing and your first match are free.
More from National Institutes of Health
See all →NIH Director’s Transformative Research Award for Individual and Group Science (R01 Clinical Trial Optional)
The NIH Director's Transformative Research Award supports collaborative investigative teams or individual scientists who propose unusually bold and innovative research projects, which, if successful, would have a major impact in a broad area of relevance to the NIH.
3 review criteria on fileNIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
S. technology development and commercialization.
6 review criteria on fileNIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)
S. technology development and commercialization.
7 review criteria on fileNIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
S. technology development and commercialization.
6 review criteria on fileAlso in clinical-research
NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)
S. technology development and commercialization.
7 review criteria on fileNIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
S. technology development and commercialization.
6 review criteria on fileNIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
S. technology development and commercialization.
6 review criteria on fileOfficial announcement: https://www.grants.gov/search-results-detail/359202Source: nih_guide+grants_gov. Always confirm dates with the funder.